Shared Risk Genes and Casual Relationships across Sex Hormone Related Traits and Alzheimer's Disease
yang, c.; Cook, N.; Zeng, Y.; Sivasankaran, S. K.; FinnGen, ; Decasien, A.; Andrews, S. J.; Belloy, M. E.
Show abstract
BackgroundAlzheimers disease (AD) exhibits marked sex differences. While sex hormone levels across the lifespan likely contribute to this, little remains known about their causal impact and their relation to sex-biased genetic risk for AD. We therefore sought to identify potential shared genetic architectures, as well as causal genes and relationships, between sex hormone-related traits and AD risk. MethodsLarge-scale AD sex-stratified genome-wide association study (GWAS) results were available from case-control, proxy-based, and population-based cohorts, including the Alzheimers Disease Genetics Consortium, Alzheimers Disease Sequencing Project, UK Biobank, and FinnGen. Sex hormone-related trait GWAS were available for age at menarche, menopause, and voice breaking, as well as testosterone, sex hormone-binding globulin (SHBG), progesterone, follicle stimulating hormone, luteinizing hormone, and estradiol levels. Cross-trait conjunctional analyses were conducted to identify pleiotropic overlap between sex-hormone traits and AD, followed by prioritization of candidate causal sex-biased AD genes through quantitative trait locus genetic colocalization analyses. The potential regulatory impact of sex hormones on these genes was assessed through transcription factor motif analyses. Finally, sex-stratified mendelian randomization analyses were used to infer causal effects of sex hormones on AD risk. ResultsGenome-wide pleiotropy analyses demonstrated enrichment of AD with testosterone, SHBG, and age-at-menarche traits in women. We identified 12 high-confidence pleiotropic loci, 9 of which showed stronger AD effect sizes in women (3 in men) and 8 that were novel. Genes at these loci were often causally implicated in brain tissues and enriched for promoter-associated androgen receptor transcription factor binding motifs. Mendelian randomization indicated higher bioavailable testosterone in women (OR:0.88; 95%-CI:0.82-0.96) and higher SHBG levels in men (OR:0.86; 95%-CI:0.77-0.96) were associated with lower AD risk. ConclusionsOur findings reveal sex-specific shared genetic architectures between AD and sex hormone-related traits and nominate related genes that may drive sex-biases in AD risk. Several of the implicated female-biased genes are relevant to phosphatidylinositol and lipid metabolism, including Fatty Acid Desaturase 2 (FADS2). While we observed no causal effect of estradiol-related traits on AD risk, the protective effects of bioavailable testosterone in women and SHBG in men provide targets for sex-informed AD risk stratification and prevention strategies.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Brain and Blood Transcriptome-Wide Association Studies Identify Five Novel Genes Associated with Alzheimer’s Disease 96%
- Exploring the genetic heterogeneity of Alzheimer’s disease: Evidence for genetic subtypes 95%
- An X Chromosome Transcriptome Wide Association Study Implicates ARMCX6 in Alzheimer's Disease 94%
Similar papers in this journal
- TREM2 Risk Variants with Alzheimer’s Disease Differ in Rate of Cognitive Decline 94%
- Age, Sex and Alzheimer's disease: A longitudinal study of 3xTg-AD mice reveals sex-specific disease trajectories and inflammatory responses mirrored in postmortem brains from Alzheimer's patients 94%
- Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer's disease 94%
Similar papers in this journal
- Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer’s disease diagnosis in a case-control analysis 96%
- Alzheimer’s Disease variant portal (ADVP): a catalog of genetic findings for Alzheimer’s Disease 95%
- Effect of Pathway-specific Polygenic Risk Scores for Alzheimer’s Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals 94%